Let’s look specifically at dexamethasone, a common corticosteroid in emergency medicine, and use current research to describe what the drug does and look at select situations in prehospital care ...

Dexamethasone provided 4 mg at every 6 hours, the usual initial dose—equivalent to 400 mg of cortisol per day—is about 20 times the normal rate of endogenous production. In patients who have ...

This interaction may account for the variations in the optimal dexamethasone dose in a large number of brain tumor patients receiving prophylactic anti-epileptic medications. Phenobarbital ...

The US Food and Drug Administration (FDA) has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer ...

Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Multiple myeloma (MM), which is caused by the transformation and uncontrolled proliferation of blood cells that normally produce antibodies 1, is the second most common haematological cancer ...